Liminatus Pharma appoints Philip Lemons and Richard Baek to Board of Directors

Liminatus Pharma, Inc.

Board expanded from 5 to 6 members with appointment of Lemons and Baek effective July 10, 2025.
Philip Lemons, 54, brings clinical R&D expertise; serves as Chief Business Officer at ICE Global Consulting.
Richard Baek, 33, brings financial oversight and regulatory compliance; VP Finance at Studio City PXL.
No arrangements or transactions with the company requiring disclosure under Item 404(a).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.